Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19Leukemia, Myeloid, Chronic-Phase 8Leukemia, Myeloid 3Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Philadelphia Chromosome 2Myeloproliferative Disorders 2Bronchiolitis Obliterans Syndrome 2Malignant Solid Tumors 1Hematologic Diseases 1HER2+ Metastatic Breast Cancer 1Burkitt Lymphoma 1Brain Neoplasms 1Blast Crisis 1

Interventions

nilotinib 2asciminib 2Dasatinib 2Cyclophosphamide 2fludarabine 1bosutinib 1Vincristine 1Prednisone 1Mitoxantrone 1Methotrexate 1Mercaptopurine 1Imatinib Mesylate 1Etoposide 1Dexamethasone 1Daunorubicin 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Philadelphia Chromosome × asciminib × 1 year × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡